CRA’s Intellectual Property experts were retained by a multinational developer and manufacturer of respiratory-related medical devices to determine economic damages in a patent infringement matter against a direct competitor. Our team developed lost profits and reasonable royalty damages models which accounted for a complex matrix of asserted patents and accused products. In determining lost profits, our team addressed demand for the patented features, market share and segmentation, and price elasticity of demand. Our team also addressed the heightened importance of the patent-practicing respiratory care medical devices amidst the global Covid-19 pandemic, including its impact on the supply chain and manufacturing capacity. CRA’s experts provided a detailed expert report and deposition testimony, and CRA’s client secured a favorable settlement just before trial.
CRA consultants recognized among leading IP professionals in the 2025 IAM Strategy 300
Daniel McGavock, Robert Goldman, and Dr. Richard Razgaitis were recognized as leading IP strategists by Intellectual Asset Management (IAM) in the latest...